Stocks quoted in this article:
Analysts are weighing in today on diagnostics specialist Cancer Genetics Inc (NASDAQ:CGIX), cloud software concern 2U Inc (NASDAQ:TWOU), and coffee company Keurig Green Mountain Inc (NASDAQ:GMCR). Here's a quick look at today's brokerage notes on CGIX, TWOU, and GMCR.
- After the company this morning announced a wider-than-forecast second-quarter loss, CGIX was hit with a price-target cut to $25 from $30 at Cantor Fitzgerald. The stock has tumbled 7.1% to trade at $9.15 this afternoon, bringing its year-to-date deficit to 33.6%. Short sellers are likely pleased by today's decline in Cancer Genetics Inc, as these skeptics ramped up their exposure by 10.8% during the past two reporting periods. Now, short interest accounts for 7% of CGIX's float, or 11.2 times the stock's average daily trading volume.
- TWOU has jumped 7.2% today to trade at $18.02, with the stock hovering just a few pennies from its newly tagged record high of $18.04. Ahead of the bell, Needham raised its price target on the shares to $22 from $18 -- revealing expectations for a continued rise from 2U Inc, which began trading in March. Today's note stands in contrast to a Goldman Sachs downgrade for TWOU earlier this week, and it also reveals higher-than-average hopes for the stock. Currently, the consensus 12-month price target among analysts is $19.14.
- GMCR is fractionally higher to trade at $114.23, after the company announced plans earlier today to raise prices on its portion packs by up to 9% in November. Buckingham Research responded by lowering its price target on Keurig Green Mountain Inc to $109 from $128, while reiterating its "neutral" rating. Even though the shares have rallied 51.5% year-to-date, skepticism is nothing new for GMCR. With a short-interest ratio of 8.2 days to cover, the stock could benefit from an unwinding of bearish bets as the positive price action continues.